Castle Biosciences Inc. has announced the publication of a new systematic review and meta-analysis evaluating the TissueCypher® Barrett's Esophagus test. The results, published in the Journal of Clinical Gastroenterology, consolidate data from six previously published studies and indicate that TissueCypher provides clinically validated risk stratification for patients with Barrett's esophagus. The analysis found that TissueCypher outperforms traditional pathology or clinical factors alone in identifying patients at increased risk of developing esophageal cancer. Patients with high or intermediate-risk results showed annual progression rates above guideline-based thresholds for intensified care. These findings have already been published and are intended to support personalized, risk-aligned patient management.